IntraBio Seeks FDA Approval for Levacetylleucine in Ataxia-Telangiectasia
Event summary
- IntraBio submitted an sNDA to the FDA for levacetylleucine (AQNEURSA®) to treat Ataxia-Telangiectasia (A-T), marking the first regulatory application for this rare disease.
- The submission is based on a Phase III trial where levacetylleucine met primary and secondary endpoints with high statistical significance.
- Levacetylleucine is currently approved for Niemann-Pick disease type C (NPC) in the U.S. and EU.
- A-T has no approved therapies, making this submission strategically significant.
The big picture
IntraBio’s sNDA for levacetylleucine in A-T represents a strategic pivot into another high-unmet-need indication, building on its existing NPC franchise. The move underscores the growing focus on repurposing approved drugs for rare diseases, particularly where no therapies exist. Success here could solidify IntraBio’s leadership in neurological rare disease treatments.
What we're watching
- Regulatory Timeline
- The pace at which the FDA reviews this sNDA will determine IntraBio’s commercialization timeline for A-T.
- Market Expansion
- Whether IntraBio can leverage its existing NPC approvals to accelerate adoption of levacetylleucine in A-T.
- Competitive Dynamics
- How this submission positions IntraBio against other rare disease players targeting neurodegenerative disorders.
Our editorial coverage: